Combining RNA Interference and RIG-I Activation to Inhibit Hepatitis E Virus Replication
Viruses · 2024
DOI: 10.3390/v16091378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Mathias Ziersch und 6 weiteren Autor:innen. Beteiligte Einrichtung: Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany. Hauptthemen laut MEDLINE: Virus Replication, Hepatitis E virus, DEAD Box Protein 58, RNA Interference. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Federal Ministry for Economic Affairs and Climate Action.
Abstract (Originalsprache)
Hepatitis E virus (HEV) poses a significant global health threat, with an estimated 20 million infections occurring annually. Despite being a self-limiting illness, in most cases, HEV infection can lead to severe outcomes, particularly in pregnant women and individuals with pre-existing liver disease. In the absence of specific antiviral treatments, the exploration of RNAi interference (RNAi) as a targeted strategy provides valuable insights for urgently needed therapeutic interventions against Hepatitis E. We designed small interfering RNAs (siRNAs) against HEV, which target the helicase domain and the open reading frame 3 (ORF3). These target regions will reduce the risk of viral escape through mutations, as they belong to the most conserved regions in the HEV genome. The siRNAs targeting the ORF3 efficiently inhibited viral replication in A549 cells after HEV infection. Importantly, the siRNA was also highly effective at inhibiting HEV in the persistently infected A549 cell line, which provides a suitable model for chronic infection in patients. Furthermore, we showed that a 5′ triphosphate modification on the siRNA sense strand activates the RIG-I receptor, a cytoplasmic pattern recognition receptor that recognizes viral RNA. Upon activation, RIG-I triggers a signaling cascade, effectively suppressing HEV replication. This dual-action strategy, combining the activation of the adaptive immune response and the inherent RNAi pathway, inhibits HEV replication successfully and may lead to the development of new therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany.
- Department of Infectious Diseases, Division of Viral Gastroenteritis and Hepatitis Pathogens and Enterovirus, Robert Koch Institute, 13353 Berlin, Germany.
- Bioprocess Engineering, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany.
- BioNukleo GmbH, Ackerstrasse 76, 13355 Berlin, Germany.
- Department of Biological Safety, German Federal Institute for Risk Assessment, 12277 Berlin, Germany.
ORCID-Profile: Dominik Harms, Lena Neumair, Reimar Johne, C-Thomas Bock, Jens Kurreck
Förderung
- Federal Ministry for Economic Affairs and Climate Action
Zitieren
APA
Ziersch, M., Harms, D., Neumair, L., Kurreck, A., Johne, R., Bock, C. T., & Kurreck, J. (2024). Combining RNA Interference and RIG-I Activation to Inhibit Hepatitis E Virus Replication. Viruses. https://doi.org/10.3390/v16091378
Vancouver
Ziersch M, Harms D, Neumair L, Kurreck A, Johne R, Bock CT, et al. Combining RNA Interference and RIG-I Activation to Inhibit Hepatitis E Virus Replication. Viruses. 2024. doi:10.3390/v16091378
BibTeX
@article{Ziersch2024,
author = {Ziersch, Mathias and Harms, Dominik and Neumair, Lena and Kurreck, Anke and Johne, Reimar and Bock, C-Thomas and Kurreck, Jens},
title = {Combining RNA Interference and RIG-I Activation to Inhibit Hepatitis E Virus Replication},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16091378}
}
EUVIMED